GAIN Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

GAIN Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of GAIN Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on GAIN Trial

CDC on GAIN Trial

GAIN Trial in the news

Blogs on GAIN Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for GAIN Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

GAIN Trial

  • GAIN trial studied the effects of atorvastatin on the progression of atherosclerosis, assessed by intra-coronary ultrasound (IVUS) in 131 patients.
  • After a 12 month follow-up period, it was found that atorvastatin reduced the progression of mean plaque volume (1.2 versus 9.6 mm3 for placebo). Also, the drug increased hyperechogenicity of the plaque which indicates a change in plaque composition from lipid-rich core to fibrotic or calcified. This change in composition of the plaque corresponds to increased plaque stability and a reduced tendency for rupture.[1]

References

  1. Schartl M, Bocksch W, Koschyk DH; et al. (2001). "Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease". Circulation. 104 (4): 387–92. PMID 11468198. Unknown parameter |month= ignored (help)